Thanks to the introduction of novel therapies in the near future, the gout disease treatment market value will increase from $989 million in 2013 to $2.28 billion by 2018, at a significant Compound Annual Growth Rate (CAGR) of 18.2%, forecasts research and consulting firm GlobalData.
The company’s latest report* states that out of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US accounted for 90% of the 2013 gout treatment sales. This was due to the wide use of Colcrys therapy, which is not generically available in the US, as well as the high prevalence of gout in the country.
The five European countries (5EU) are now experiencing a dramatic increase in gout prevalence, which is 2.3 times faster than in the US. By the end of the forecast period, GlobalData expects the 5EU to have a market share of 12.5%.
Valentina Gburcik, Ph.D., GlobalData's Analyst covering Cardiovascular & Metabolic Disorders, says: “With the recent approval of the powerful anti-inflammatory therapy Ilaris, and the market entry of two novel urate-lowering therapies, lesinurad and ulodesine, physicians will have more options available to tackle difficult-to-treat gout.”
However, Gburcik says that despite advances in gout disease treatment, physician education remains the greatest unmet need in the gout therapeutics market.
The analyst continues: “The standard treatments are effective in most gout patients, therefore making gout a potentially curable disease. However, there is a growing number of patients for whom the standard therapies are inappropriate.
“Since most physicians still do not take gout seriously enough, they are passing on this attitude to their patients, who are consequently unaware of the importance of keeping their urate levels down and are not sticking to the appropriate therapy. This in turn is leading to an increase in the difficult-to-treat patient pool,” Gburcik concludes.
*OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018
This report provides an overview of gout disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also provides annualized gout therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 to 2018.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
Get more details @ http://www.rnrmarketresearch.com/opportunityanalyzer-gout-opportunity-analysis-and-forecast-to-2018-market-report.html
The company’s latest report* states that out of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US accounted for 90% of the 2013 gout treatment sales. This was due to the wide use of Colcrys therapy, which is not generically available in the US, as well as the high prevalence of gout in the country.
The five European countries (5EU) are now experiencing a dramatic increase in gout prevalence, which is 2.3 times faster than in the US. By the end of the forecast period, GlobalData expects the 5EU to have a market share of 12.5%.
Valentina Gburcik, Ph.D., GlobalData's Analyst covering Cardiovascular & Metabolic Disorders, says: “With the recent approval of the powerful anti-inflammatory therapy Ilaris, and the market entry of two novel urate-lowering therapies, lesinurad and ulodesine, physicians will have more options available to tackle difficult-to-treat gout.”
However, Gburcik says that despite advances in gout disease treatment, physician education remains the greatest unmet need in the gout therapeutics market.
The analyst continues: “The standard treatments are effective in most gout patients, therefore making gout a potentially curable disease. However, there is a growing number of patients for whom the standard therapies are inappropriate.
“Since most physicians still do not take gout seriously enough, they are passing on this attitude to their patients, who are consequently unaware of the importance of keeping their urate levels down and are not sticking to the appropriate therapy. This in turn is leading to an increase in the difficult-to-treat patient pool,” Gburcik concludes.
*OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018
This report provides an overview of gout disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also provides annualized gout therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 to 2018.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
Get more details @ http://www.rnrmarketresearch.com/opportunityanalyzer-gout-opportunity-analysis-and-forecast-to-2018-market-report.html